D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 108 Citations 44,656 773 World Ranking 2693 National Ranking 57

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

Pier Luigi Zinzani focuses on Internal medicine, Lymphoma, Surgery, Gastroenterology and Chemotherapy. In most of his Internal medicine studies, his work intersects topics such as Oncology. His study in Oncology is interdisciplinary in nature, drawing from both Progressive disease, Clinical trial, Etoposide, Brentuximab vedotin and Hodgkin's lymphoma.

He has researched Lymphoma in several fields, including Peripheral T-cell lymphoma and Positron emission tomography, Nuclear medicine. The concepts of his Gastroenterology study are interwoven with issues in Phases of clinical research, T-cell lymphoma, Neutropenia, Survival analysis and Fludarabine. Pier Luigi Zinzani interconnects CHOP, Maintenance therapy, Diffuse large B-cell lymphoma, Follicular lymphoma and CD20 in the investigation of issues within Rituximab.

His most cited work include:

  • CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group (1582 citations)
  • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial (1433 citations)
  • Follicular lymphoma international prognostic index. (1297 citations)

What are the main themes of his work throughout his whole career to date?

The scientist’s investigation covers issues in Internal medicine, Oncology, Lymphoma, Surgery and Gastroenterology. His is doing research in Rituximab, Chemotherapy, Refractory, Regimen and Neutropenia, both of which are found in Internal medicine. The various areas that Pier Luigi Zinzani examines in his Chemotherapy study include Stage and Survival rate.

His Oncology research incorporates themes from Brentuximab vedotin, Follicular lymphoma, Immunology and Phases of clinical research. His studies in Lymphoma integrate themes in fields like Positron emission tomography, Radiation therapy, Radiology and Nuclear medicine. The Gastroenterology study combines topics in areas such as Hairy cell leukemia, Tolerability and Toxicity.

He most often published in these fields:

  • Internal medicine (63.12%)
  • Oncology (36.77%)
  • Lymphoma (34.73%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (63.12%)
  • Oncology (36.77%)
  • Lymphoma (34.73%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Oncology, Lymphoma, Brentuximab vedotin and Refractory. Internal medicine is frequently linked to Gastroenterology in his study. The study incorporates disciplines such as Regimen and Tolerability in addition to Gastroenterology.

His work in Oncology tackles topics such as Diffuse large B-cell lymphoma which are related to areas like Lenalidomide and Cancer. His Lymphoma study combines topics in areas such as Progressive disease, Biopsy, Clinical trial and Progression-free survival. His research integrates issues of Pembrolizumab, Peripheral T-cell lymphoma, Chemotherapy and Transplantation in his study of Brentuximab vedotin.

Between 2018 and 2021, his most popular works were:

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial (182 citations)
  • Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma (125 citations)
  • Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087 (79 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Chemotherapy

His primary areas of study are Internal medicine, Oncology, Lymphoma, In patient and Refractory. Brentuximab vedotin, Follicular lymphoma, Neutropenia, Phases of clinical research and Adverse effect are among the areas of Internal medicine where the researcher is concentrating his efforts. His research in Follicular lymphoma intersects with topics in Gastroenterology and Rituximab.

His biological study spans a wide range of topics, including Open label, Diffuse large B-cell lymphoma, Hodgkin lymphoma, Relapsed refractory and Poor prognosis. His Lymphoma research is multidisciplinary, incorporating perspectives in T cell, Hematology, Cyclophosphamide, Regulation of gene expression and Nivolumab. His Refractory study integrates concerns from other disciplines, such as Pembrolizumab and Primary Mediastinal Large B-Cell Lymphoma.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

Michael Pfreundschuh;Lorenz Trümper;Anders Österborg;Ruth Pettengell.
Lancet Oncology (2006)

2620 Citations

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

Michael Hallek;K. Fischer;Gunter Fingerle-Rowson;Anne Michelle Fink.
The Lancet (2010)

2061 Citations

Follicular lymphoma international prognostic index.

Philippe Solal-Céligny;Pascal Roy;Philippe Colombat;Josephine White.
Blood (2004)

1805 Citations

PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston.
The New England Journal of Medicine (2014)

935 Citations

ALK+ Lymphoma: Clinico-Pathological Findings and Outcome

Brunangelo Falini;Stefano Pileri;Pier Luigi Zinzani;Antonino Carbone.
Blood (1999)

733 Citations

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani.
Lancet Oncology (2016)

716 Citations

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

Michael Pfreundschuh;Evelyn Kuhnt;Lorenz Trümper;Anders Österborg.
Lancet Oncology (2011)

680 Citations

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Robert Chen;Pier Luigi Zinzani;Michelle A. Fanale;Philippe Armand.
Journal of Clinical Oncology (2017)

666 Citations

Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients.

S A Pileri;S Ascani;M C Cox;C Campidelli.
Leukemia (2007)

619 Citations

Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue.

Emanuele Zucca;Annarita Conconi;Ennio Pedrinis;Sergio Cortelazzo.
Blood (2003)

574 Citations

Best Scientists Citing Pier Luigi Zinzani

Michael Hallek

Michael Hallek

University of Cologne

Publications: 169

Gilles Salles

Gilles Salles

Memorial Sloan Kettering Cancer Center

Publications: 160

Stefano Pileri

Stefano Pileri

European Institute of Oncology

Publications: 146

Stephen M. Ansell

Stephen M. Ansell

Mayo Clinic

Publications: 145

John F. Seymour

John F. Seymour

Peter MacCallum Cancer Centre

Publications: 127

Martin Dreyling

Martin Dreyling

Ludwig-Maximilians-Universität München

Publications: 124

Randy D. Gascoyne

Randy D. Gascoyne

BC Cancer Agency

Publications: 118

Tadeusz Robak

Tadeusz Robak

Medical University of Lodz

Publications: 116

Emanuele Zucca

Emanuele Zucca

Universita della Svizzera Italiana

Publications: 115

Jonathan W. Friedberg

Jonathan W. Friedberg

University of Rochester

Publications: 114

Susan O'Brien

Susan O'Brien

University of California, Irvine

Publications: 112

Andreas Engert

Andreas Engert

University of Cologne

Publications: 101

Bruce D. Cheson

Bruce D. Cheson

Georgetown University

Publications: 99

Anas Younes

Anas Younes

AstraZeneca

Publications: 98

Bertrand Coiffier

Bertrand Coiffier

University of Lyon System

Publications: 97

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.